Values First Advisors Inc. Makes New $52,000 Investment in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Values First Advisors Inc. bought a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the third quarter, Holdings Channel reports. The firm bought 2,685 shares of the biotechnology company’s stock, valued at approximately $52,000.

Several other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in shares of Arrowhead Pharmaceuticals by 16.2% during the first quarter. Vanguard Group Inc. now owns 12,404,050 shares of the biotechnology company’s stock valued at $354,756,000 after buying an additional 1,731,974 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in shares of Arrowhead Pharmaceuticals by 3.9% during the second quarter. Avoro Capital Advisors LLC now owns 8,888,888 shares of the biotechnology company’s stock valued at $231,022,000 after purchasing an additional 333,333 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Arrowhead Pharmaceuticals by 2.9% during the second quarter. Bank of New York Mellon Corp now owns 1,085,069 shares of the biotechnology company’s stock worth $28,201,000 after purchasing an additional 30,086 shares during the last quarter. Millennium Management LLC increased its stake in Arrowhead Pharmaceuticals by 61.9% in the 2nd quarter. Millennium Management LLC now owns 529,251 shares of the biotechnology company’s stock valued at $13,755,000 after buying an additional 202,280 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Arrowhead Pharmaceuticals by 17.5% in the 1st quarter. Principal Financial Group Inc. now owns 484,120 shares of the biotechnology company’s stock worth $13,846,000 after buying an additional 72,273 shares during the last quarter. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Stock Performance

Arrowhead Pharmaceuticals stock opened at $20.10 on Friday. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $17.05 and a fifty-two week high of $39.83. The firm’s fifty day moving average price is $21.09 and its 200-day moving average price is $23.74.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.80). Arrowhead Pharmaceuticals’s revenue was down 100.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.96) earnings per share. On average, equities analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -4.31 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on ARWR shares. Royal Bank of Canada reiterated an “outperform” rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, September 9th. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research report on Thursday, October 17th. Chardan Capital reaffirmed a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, July 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Friday, October 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Arrowhead Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $45.33.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.